NCT04270461 is a Phase 1 clinical trial of NKG2D-based CAR T-cells in Hepatocellular Carcinoma, sponsored by Jiujiang University Affiliated Hospital.

Who is sponsoring NCT04270461?

NCT04270461 is sponsored by Jiujiang University Affiliated Hospital.

What drugs are being tested in NCT04270461?

Interventions in NCT04270461: NKG2D-based CAR T-cells.

What condition does NCT04270461 study?

NCT04270461 studies Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer.

Is NCT04270461 still recruiting?

NCT04270461 is currently withdrawn. Last updated 22 October 2020.

Last reviewed 2020-10-22 · How we verify

NCT04270461

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Withdrawn Phase 1 Last updated 22 October 2020

What this trial tests

Phase 1 trial testing NKG2D-based CAR T-cells in Hepatocellular Carcinoma. Withdrawn.

Timeline

17 March 2020

Primary endpoint
17 October 2020

17 October 2020

Quick facts

Lead sponsor	Jiujiang University Affiliated Hospital
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	17 March 2020
Primary completion	17 October 2020
Estimated completion	17 October 2020
Sites	1 location across China

Drugs / interventions tested

NKG2D-based CAR T-cells — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Glioblastoma — all drugs for Glioblastoma →
Medulloblastoma — all drugs for Medulloblastoma →
Colon Cancer — all drugs for Colon Cancer →

Sponsor

Jiujiang University Affiliated Hospital

Who can join

Adults 18 to 75, any sex, with Hepatocellular Carcinoma or Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment.
Yan T, Zhu L, Chen J. · · 2023 · cited 132× · PMID 36707873 · DOI 10.1186/s40164-023-00373-7
CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma.
Maggs L, Cattaneo G, Dal AE, Moghaddam AS, et al · · 2021 · cited 113× · PMID 34113233 · DOI 10.3389/fnins.2021.662064
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD, Cuzzubbo S, McArthur S, Durrant LG, et al · · 2020 · cited 92× · PMID 33178210 · DOI 10.3389/fimmu.2020.582106
Glioblastoma Immune Landscape and the Potential of New Immunotherapies.
Daubon T, Hemadou A, Romero Garmendia I, Saleh M. · · 2020 · cited 89× · PMID 33154756 · DOI 10.3389/fimmu.2020.585616
Liver Cancer Immunity.
Ilyas SI, Wang J, El-Khoueiry AB. · · 2021 · cited 81× · PMID 32516437 · DOI 10.1002/hep.31416
A summary of current NKG2D-based CAR clinical trials.
Curio S, Jonsson G, Marinović S. · · 2021 · cited 63× · PMID 34604863 · DOI 10.1093/immadv/ltab018
Tumor-infiltrating CD8<sup>+</sup> T cell antitumor efficacy and exhaustion: molecular insights.
Kumar S, Singh SK, Rana B, Rana A. · · 2021 · cited 57× · PMID 33450394 · DOI 10.1016/j.drudis.2021.01.002
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.
Aparicio C, Belver M, Enríquez L, Espeso F, et al · · 2021 · cited 55× · PMID 34769211 · DOI 10.3390/ijms222111781

Verify or expand the search:

Other trials of NKG2D-based CAR T-cells

Trials testing the same drug.

NCT05131763 — NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors · Phase 1 · unknown

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04270461 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiujiang University Affiliated Hospital
Last refreshed: 22 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04270461.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing